A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 41/00 (2006.01) A61K 31/409 (2006.01) A61K 31/573 (2006.01) A61K 39/395 (2006.01) A61P 9/00 (2006.01) A61P 27/00 (2006.01)
Patent
CA 2747219
The use of a combination of photodynamic therapy and an anti-VEGF agent in the treatment of conditions characterized by unwanted choroidal neovasculature is described. These conditions include wet age-related macular degeneration Preferred anti-VEGF agents are antibodies such as bevacizumab or ranibizumab Photosensitizers may be selected from green porphyrins such as BPD-MA (verteporfin) and the photodynamic activation of the photosensitizer may be accomplished using a reduced fluence rate. The use may further comprises an anti-inflammatory agent such a dexamethasone.
La présente invention concerne l'utilisation d'une combinaison d'une thérapie photodynamique et d'un agent anti-VEGF dans le traitement d'états caractérisés par une néovascularisation choroïdienne indésirable, et notamment de la dégénérescence maculaire liée à l'âge humide. Les agents anti-VEGF préférés sont des anticorps tels que le bévacizumab ou le ranibizumab. Le photosensibilisateur peut être choisi parmi les porphyrines vertes telles que le BPD-MA (vertéporfine), et l'activation photodynamique du photosensibilisateur peut être effectuée en utilisant une densité de flux réduite. L'utilisation peut comprendre en outre un anti-inflammatoire tel que la dexaméthasone.
Hao Yong
Strong Andrew
Fetherstonhaugh & Co.
Qlt Inc.
LandOfFree
Combination of photodynamic therapy and anti-vegf agents in... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Combination of photodynamic therapy and anti-vegf agents in..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combination of photodynamic therapy and anti-vegf agents in... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1914868